Pailin Biotech announced that net profit attributable to shareholders of listed companies for the first half year of 2026 is expected to be 80 million yuan to 110 million yuan, down 53.35%-66.07% from the profit of 236 million yuan in the same period last year; net profit after deducting non-recurring profit and loss is 60 million yuan to 90 million yuan, down 58.07%-72.05% from the profit of 215 million yuan in the same period last year; basic earnings per share are 0.08 yuan/share - 0.12 yuan/share. The decline in performance is mainly due to factors such as the expansion of the blood products industry, DRG/DIP reform, medical insurance control fees, and drug priority monitoring and rational drug use, resulting in a year-on-year decline in gross margin. Furthermore, blood products will no longer be included in the scope of simple levy of 3% value-added tax from January 1, 2026, and a 13% general taxation model will be implemented, which further led to a year-on-year decline in gross margin.

Pailin Biotech announced that net profit attributable to shareholders of listed companies for the first half year of 2026 is expected to be 80 million yuan to 110 million yuan, down 53.35%-66.07% from the profit of 236 million yuan in the same period last year; net profit after deducting non-recurring profit and loss is 60 million yuan to 90 million yuan, down 58.07%-72.05% from the profit of 215 million yuan in the same period last year; basic earnings per share are 0.08 yuan/share - 0.12 yuan/share. The decline in performance is mainly due to factors such as the expansion of the blood products industry, DRG/DIP reform, medical insurance control fees, and drug priority monitoring and rational drug use, resulting in a year-on-year decline in gross margin. Furthermore, blood products will no longer be included in the scope of simple levy of 3% value-added tax from January 1, 2026, and a 13% general taxation model will be implemented, which further led to a year-on-year decline in gross margin.